<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03092180</url>
  </required_header>
  <id_info>
    <org_study_id>MYO-HCFMUSP-01</org_study_id>
    <nct_id>NCT03092180</nct_id>
  </id_info>
  <brief_title>Optimizing Treatment on Idiopathic Inflammatory Myopathies</brief_title>
  <official_title>Optimizing Treatment on Idiopathic Inflammatory Myopathies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Sao Paulo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      As a T2T, our patients with idiopathic inflammatory myopathies will receive pulse therapies
      with methyprednisolone and/or human intravenous immunoglobulin, or only methyprednisolone at
      disease onset.

      This scheme is an internal routine protocol of our Service.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To compare two groups of patients as described in Brief Summary.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Anticipated">January 2026</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Physician Global Activity</measure>
    <time_frame>Six months</time_frame>
    <description>This partially validated tool measures the global evaluation by the treating physician of the overall disease activity of the patient at the time of assessment using a 10 cm. visual analogue scale and a 5 point Likert scale.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient/Parent Global Activity -</measure>
    <time_frame>Six months</time_frame>
    <description>This partially validated tool measures the global evaluation by the patient, or by the parent if the patient is a minor, of the patient's overall disease activity at the time of assessment using a 10 cm. visual analogue scale.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Manual Muscle Testing</measure>
    <time_frame>Six months</time_frame>
    <description>This partially validated tool assesses muscle strength using manual muscle testing (MMT). A 0 - 10 point scale is proposed for use. An abbreviated group of 8 proximal, distal, and axial muscles performs similarly to a total of 24 muscle groups, and is also proposed for use for research studies.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Health Assessment Questionnaire</measure>
    <time_frame>Six months</time_frame>
    <description>Define the health assessement questionnaire. Pontuaction: 0.00-3.00</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Muscle Enzymes</measure>
    <time_frame>Six months</time_frame>
    <description>This partially validated tool measures the serum activities of at least 2 of the 4 muscle-associated enzymes including creatine phosphokinase (CK), the transaminases (ALT, AST), lactate dehydrogenase (LD) and aldolase.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Myositis Disease Activity Assessment Tool</measure>
    <time_frame>Six months</time_frame>
    <description>After local anesthesia, a cutaneous incision will be made in lateral thigh face. The biopsy will be done using the Bergstrom needle. Histological (hematoxylin and eosin)/immunohistochemical (CD4, CD8, CD68, CD20, C5b-9, MHCI, MHCII, CD31) analysis will be performed in muscle samples (at baseline and after 12 weeks) in all patients (present study)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Side effects to treatment (glucocorticoid, immunosuppressants and/or human intravenous immunoglobulin)</measure>
    <time_frame>Six months</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Idiopathic Inflammatory Myopathies</condition>
  <arm_group>
    <arm_group_label>Idiopathic inflammatory myopathies 1</arm_group_label>
    <description>Intravenous infusion with methyprednisolone / human intravenous immunoglobulin at disease onset</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Idiopathic inflammatory myopathies 2</arm_group_label>
    <description>Intravenous infusion with methyprednisolone at disease onset</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous Infusion</intervention_name>
    <description>Intravenous infusion of follow medicine at disease onset: methyprednisolone and/or human intravenous immunoglobulin</description>
    <arm_group_label>Idiopathic inflammatory myopathies 1</arm_group_label>
    <arm_group_label>Idiopathic inflammatory myopathies 2</arm_group_label>
    <other_name>Medicine</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum and muscle biopsies

      NOTE: This is a observational study. Subjects in the study will receive a routine care that
      has been established in our Instituition (diagnostic, therapeutic, biospecimen analysis and
      retention).
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Idiopathic inflammatory myopathies
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Idiopathic inflammatory myopathies

        Exclusion Criteria:

          -  Inclusion body myositis, muscular dystrophies, neoplasia-associated myopathies,
             overlapped myopathies, others myopathies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Samuel K Shinjo, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universidade de Sao Paulo - Rheumatology Division</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Samuel K Shinjo, PhD</last_name>
    <phone>55-11-3061-7176</phone>
    <email>samuel.shinjo@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Samuel Katsuyuki Shinjo</name>
      <address>
        <city>Sao Paulo</city>
        <zip>01246903</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 9, 2017</study_first_submitted>
  <study_first_submitted_qc>March 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2017</study_first_posted>
  <last_update_submitted>May 9, 2018</last_update_submitted>
  <last_update_submitted_qc>May 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Sao Paulo</investigator_affiliation>
    <investigator_full_name>Samuel Katsuyuki Shinjo, PhD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Dermatomyositis</keyword>
  <keyword>Immunomodulation</keyword>
  <keyword>Immunosuppressive agents</keyword>
  <keyword>Myositis</keyword>
  <keyword>Polymyositis</keyword>
  <keyword>Necrotizing myopathies</keyword>
  <keyword>Antisynthetase syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Diseases</mesh_term>
    <mesh_term>Myositis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>gamma-Globulins</mesh_term>
    <mesh_term>Rho(D) Immune Globulin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

